Tag Archives: pricing

Wins and Losses from Risk-Sharing Agreements

By William Looney | Published: November 17, 2010
Can you manage the external market impact? Risk-sharing agreements – where companies contract with reimbursement or assessment authorities to guarantee a new drug’s performance, often against specific outcomes measures, in return for access to patients – are among the latest innovations in managing health care costs. Use of the tool is standard in Australia, is [...]
Posted in Europe, Global, Regulatory, Strategy, healthcare, pricing | Also tagged , , , , , | Leave a comment

NICE News or Bad News?

By William Looney | Published: November 3, 2010
Far from losing its mojo, the UK’s National Institute for Health and Clinical Excellence (NICE) will simply be sharing the stage with a range of new players under NHS reform — none of whom look supportive of the R&D industry. The big issue for industry in the UK this week is handicapping the future of its [...]
Posted in Europe, Global, Regulatory | Also tagged , , , , , , , | Leave a comment

Lower Lilly Earnings the Shape of Things to Come

By Oriana Schwindt | Published: April 21, 2010
Eli Lilly announced its first quarter financial results on April 19. But even though the company trumpeted a global revenue growth rate of 9 percent—$5.49 billion, compared to Q1 2009’s $5.05 billion—net income fell 5 percent to $1.25 billion. Part of the blame for that 4 percent difference, the company said, lies with the passage of [...]
Posted in Strategy | Also tagged , , , , , | Leave a comment